New Future For Admedus Immunotherapies? – Not Yet
Admedus is mulling over the future of its vaccines business.
You may also be interested in...
The ups, downs – and nearly outs – of ASX-listed health technologies manufacturer and distributor Admedus have made compelling reading in the past two years, but CEO Wayne Paterson has brought a competitive edge to a company that was lacking focus. Now he is looking to raise the bar again, aiming to use the company's proprietary Adapt patch technology in the TAVR space, while also pressing on with strategic plans for the therapeutic vaccines portfolio and adding scale.
A new deal with an aortic ring manufacturer, a change of chairman, a hike in the number of centers using its cardiovascular bioscaffold and plans to develop an aortic valve repair scaffold have attracted much attention to Admedus in the past six months. The Australian company’s immunotherapies platform is also advancing well, says CEO Lee Rodne.
The operating environment for medical technology companies becomes more complex, competitive and costly every year. There is no expectation that 2022 will buck that trend, even as the medtech sector prepares for a third year of working under conditions shaped by the COVID-19 pandemic.